{"paper_id":"98911180-e4ab-4cbe-b96a-77001bed3310","body_text":"Abstract\nIntroduction\nHormone therapy is widely used in the treatment of patients with ovarian endometriosis after surgery, and progestin and gonadotropin-releasing hormone (GnRH) are two of the most widely used hormones. This study aimed to compare the outcomes of progestin and GnRH in the treatment of ovarian endometriosis after surgery.\nMethods\nA total of 399 patients with ovarian endometriosis were included and divided into four groups to receive different treatments. Group A received no postoperative hormone therapy; patients in group B1 and B2 were treated with different doses of norethindrone (progestin, 1.2 and 5 mg/day, respectively); patients in group C were treated with GnRH (2.0 mg every 2 weeks). Treatment outcomes including menstrual bleeding profiles, cumulative recurrence rate, incidence of complications, and endometrioma diameter in the case of recurrence were recorded and compared between groups.\nResults\nCompared with group A, group B1, B2 and C showed significantly improved menstrual bleeding profiles and reduced cumulative recurrence rate and endometrioma diameter after recurrence. In addition, compared with group C, menstrual bleeding profiles were significantly improved and cumulative recurrence rate and endometrioma diameter were significantly reduced in group B1 and B2. No significant differences in incidence of complications during treatment were found among groups. After treatment, recurrence rate and endometrioma diameter were significantly increased in group B1, B2, and C.\nConclusion\nBoth progestin and GnRH can significantly improve the conditions of patients with ovarian endometriosis after surgery, but progestin may be a better choice. Both therapies are challenged by the increased recurrence rate and endometrioma diameter after treatment.\nReferences\nVercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–75.\nNisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril. 1997;68(4):585–96.\nBulun SE. Ovarian endometriosis: the nemesis of eggs. Fertil Steril. 2014;101(4):938.\nDuffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev. 2014;(4)CD011031.\nCucinella G, Granese R, Calagna G, et al. Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference? Arch Gynecol Obstet. 2013;288(4):821–7.\nSomigliana E, Vercellini P, Vigano P, et al. Postoperative medical therapy after surgical treatment of endometriosis: from adjuvant therapy to tertiary prevention. J Minim Invasive Gynecol. 2014;21(3):328–34.\nSurrey ES, Katz-Jaffe M, Kondapalli LV, et al. GnRH agonist administration prior to embryo transfer in freeze-all cycles of patients with endometriosis or aberrant endometrial integrin expression. Reprod BioMed Online. 2017;35(2):145–51.\nShao R, Cao S, Wang X, et al. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res. 2014;6(2):104.\nThe American Fertility Society. Revised American Fertility Society classification of ovarian endometriosis. Fertil Steril. 1985;43:351–2.\nNnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–73.e8.\nRogers PAW, D’Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16(4):335–46.\nZhao L, Yang H, Xuan Y, et al. Increased expression of fibroblast growth factor receptor 1 in endometriosis and its correlation with endometriosis-related dysmenorrhea and recurrence. Eur J Obstet Gynecol Reprod Biol. 2015;184:117–24.\nChapron C, Fauconnier A, Dubuisson JB, et al. Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease. Hum Reprod. 2003;18(4):760–6.\nWardle J. Endometriosis and menorrhagia. In: Sarris J, Wardle J, editors. Clinical naturopathy: in practice. Chatswood: Elsevier; 2017. p. 110.\nSriprasert I, Beydoun H, Barnabei V, et al. Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension. Menopause. 2015;22(10):1067–75.\nWu B, Yang Z, Tobe RG, Wang Y. Medical therapy for preventing recurrent endometriosis after conservative surgery: a cost-effectiveness analysis. BJOG. 2018;125(4):469–77.\nZheng Q, Mao H, Xu Y, et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016;294(1):201–7.\nOuchi N, Akira S, Mine K, et al. Recurrence of ovarian endometrioma after laparoscopic excision: risk factors and prevention. J Obstet Gynaecol Res. 2014;40(1):230–6.\nLee SY, Kim ML, Seong SJ, et al. Recurrence of ovarian endometrioma in adolescents after conservative, laparoscopic cyst enucleation. J Pediatr Adolesc Gynecol. 2017;30(2):228–33.\nBrosens I, Gordts S, Puttemans P, et al. Pathophysiology proposed as the basis for modern management of the ovarian endometrioma. Reprod BioMed Online. 2014;28(2):232–8.\nAcknowledgements\nWe thank the participants of the study.\nFunding\nNo funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors.\nAuthorship\nAll authors including Songnan Zhu, Yingjun Zhu, Yabo Liu, and Hong Zhang meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.\nDisclosures\nSongnan Zhu, Yingjun Zhu, Yabo Liu, and Hong Zhang have nothing to disclose.\nCompliance with Ethics Guidelines\nThis study was approved by the ethics committee of Tianjin Central Obstetrics and Gynecology Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.\nData Availability\nThe data sets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nAdditional information\nEnhanced digital features\nTo view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.6210047.\nRights and permissions\nAbout this article\nCite this article\nZhu, S., Zhu, Y., Liu, Y. et al. Comparison of Outcomes of Different Postoperative Hormone Therapy in the Treatment of Ovarian Endometriosis: A Brief Report. Adv Ther 35, 857–863 (2018). https://doi.org/10.1007/s12325-018-0715-z\nReceived:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s12325-018-0715-z","source_license":"CC0","license_restricted":false}